Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Terminated
3(25%)

Phase Distribution

Ph phase_2
4
33%
Ph phase_3
1
8%
Ph not_applicable
6
50%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
1(9.1%)
N/ANon-phased studies
6(54.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

41.7%

5 of 12 finished

Non-Completion Rate

58.3%

7 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(5)
Terminated(7)

Detailed Status

Completed5
Withdrawn4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
62.5%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (36.4%)
Phase 31 (9.1%)
N/A6 (54.5%)

Trials by Status

completed542%
terminated325%
withdrawn433%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
withdrawnphase_2

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

NCT00373152
completed

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

NCT00033397
terminatednot_applicable

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02967380
terminatedphase_2

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

NCT00019604
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00375830Phase 2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Completed
NCT00373152Phase 2

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

Withdrawn
NCT00033397

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

Completed
NCT02967380Not Applicable

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Terminated
NCT00019604Phase 2

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

Terminated
NCT02371798Not Applicable

Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?

Withdrawn
NCT00060008Not Applicable

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Terminated
NCT01416740Not Applicable

A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation

Withdrawn
NCT00043017Phase 2

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

Completed
NCT00004936Not Applicable

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

Completed
NCT00005790Not Applicable

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

Withdrawn
NCT01260636Phase 3

Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries

Completed

All 12 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
12